Inhibiting fusion with cellular membrane system: therapeutic options to prevent severe acute respiratory syndrome coronavirus-2 infection

Severe acute respiratory syndrome coronavirus (SARS-CoV), an enveloped virus with a positive-sense single-stranded RNA genome, facilitates the host cell entry through intricate interactions with proteins and lipids of the cell membrane. The detailed molecular mechanism involves binding to the host cell receptor and fusion at the plasma membrane or after being trafficked to late endosomes under favorable environmental conditions. A crucial event in the process is the proteolytic cleavage of the viral spike protein by the host’s endogenous proteases that releases the fusion peptide enabling fusion with the host cellular membrane system. The present review details the mechanism of viral fusion with the host and highlights the therapeutic options that prevent SARS-CoV-2 entry in humans.

• Publication year

  2020

• Venue

  American Journal of Physiology - Cell Physiology

• Publication date

  2020-07-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1152/ajpcell.00260.2020PMID 32687406PMCID 7839238
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

  2020cited by this paper
• SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

  2020influential reference
• Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.

  2020cited by this paper
• The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

  2020cited by this paper
• A Novel Coronavirus from Patients with Pneumonia in China, 2019

  2020cited by this paper
• Convalescent serum lines up as first-choice treatment for coronavirus

  2020cited by this paper
• A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

  2020influential reference
• A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing

  2020influential reference
• Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome

  2020cited by this paper
• Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic

  2020cited by this paper
• SARS‐CoV‐2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells

  2020cited by this paper
• Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients

  2020cited by this paper
• Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).

  2020cited by this paper
• Coronavirus membrane fusion mechanism offers a potential target for antiviral development

  2020influential reference
• Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

  2020influential reference
• Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

  2020cited by this paper
• A human monoclonal antibody blocking SARS-CoV-2 infection

  2020cited by this paper
• Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

  2020influential reference
• Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

  2020cited by this paper
• A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2

  2020cited by this paper
• New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

  2020cited by this paper
• Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19

  2020cited by this paper
• Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

  2020influential reference
• Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

  2020cited by this paper
• From SARS to COVID-19: What we have learned about children infected with COVID-19

  2020cited by this paper
• Anticancer autophagy inhibitors attract ‘resurgent’ interest

  2019cited by this paper
• Membrane binding proteins of coronaviruses

  2019cited by this paper
• TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection

  2019cited by this paper
• Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells

  2017influential reference
• Structure, Function, and Evolution of Coronavirus Spike Proteins.

  2016influential reference
• Surface vimentin is critical for the cell entry of SARS-CoV

  2016cited by this paper
• Safe and Sensitive Antiviral Screening Platform Based on Recombinant Human Coronavirus OC43 Expressing the Luciferase Reporter Gene

  2016cited by this paper
• Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion

  2016cited by this paper
• Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism

  2016cited by this paper
• Calpain research for drug discovery: challenges and potential

  2016cited by this paper
• Therapeutic uses of furin and its inhibitors: a patent review

  2015cited by this paper
• Augmentation of Cationic Antimicrobial Peptide Production with Histone Deacetylase Inhibitors as a Novel Epigenetic Therapy for Bacterial Infections

  2015influential reference
• Expanded View Figures

  2015cited by this paper
• A Serpin Shapes the Extracellular Environment to Prevent Influenza A Virus Maturation

  2015influential reference
• Protease inhibitors targeting coronavirus and filovirus entry

  2015cited by this paper
• Coronavirus Cell Entry Occurs through the Endo-/Lysosomal Pathway in a Proteolysis-Dependent Manner

  2014cited by this paper
• A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy.

  2014cited by this paper
• Mechanisms of Virus Membrane Fusion Proteins.

  2014cited by this paper
• Role of the Spike Glycoprotein of Human Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Virus Entry and Syncytia Formation

  2013cited by this paper
• Crystal Structure of the Receptor-Binding Domain from Newly Emerged Middle East Respiratory Syndrome Coronavirus

  2013cited by this paper
• Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4

  2013cited by this paper
• Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency

  2012cited by this paper
• Influenza and SARS-Coronavirus Activating Proteases TMPRSS2 and HAT Are Expressed at Multiple Sites in Human Respiratory and Gastrointestinal Tracts

  2012cited by this paper
• Phosphoinositides and vesicular membrane traffic.

  2012cited by this paper
• A Virus-Binding Hot Spot on Human Angiotensin-Converting Enzyme 2 Is Critical for Binding of Two Different Coronaviruses

  2011cited by this paper
• Evidence for a Common Evolutionary Origin of Coronavirus Spike Protein Receptor-Binding Subunits

  2011cited by this paper
• Inhibition of lung serine proteases in mice: a potentially new approach to control influenza infection

  2011cited by this paper
• Histidine-rich human salivary peptides are inhibitors of proprotein convertases furin and PC7 but act as substrates for PC1.

  2009cited by this paper
• Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor

  2009influential reference
• Intracellular and extracellular serpins modulate lung disease

  2008cited by this paper
• Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level.

  2008cited by this paper
• Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents.

  2007influential reference
• Mycobacterium bovis BCG disrupts the interaction of Rab7 with RILP contributing to inhibition of phagosome maturation

  2007cited by this paper
• SARS Coronavirus, but Not Human Coronavirus NL63, Utilizes Cathepsin L to Infect ACE2-expressing Cells

  2006cited by this paper
• Regulation of membrane traffic by phosphoinositide 3-kinases

  2006cited by this paper
• Human Immunodeficiency Virus Type 1 Stimulates the Expression and Production of Secretory Leukocyte Protease Inhibitor (SLPI) in Oral Epithelial Cells: a Role for SLPI in Innate Mucosal Immunity

  2005cited by this paper
• Enfuvirtide, a New Fusion Inhibitor for Therapy of Human Immunodeficiency Virus Infection

  2004cited by this paper
• A novel phosphatidylinositol(3,4,5)P3 pathway in fission yeast

  2004cited by this paper
• Identification of an Antigenic Determinant on the S2 Domain of the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Capable of Inducing Neutralizing Antibodies

  2004cited by this paper
• Mini-plasmin found in the epithelial cells of bronchioles triggers infection by broad-spectrum influenza A viruses and Sendai virus.

  2001cited by this paper
• Cysteine Proteases and Their Inhibitors.

  1997cited by this paper
• Inhibition of intracellular proteolytic processing of soluble proproteins by an engineered alpha 2-macroglobulin containing a furin recognition sequence in the bait region.

  1997cited by this paper
• Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.

  1995cited by this paper
• Secretion of mucus proteinase inhibitor and elafin by Clara cell and type II pneumocyte cell lines.

  1993cited by this paper
• Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein.

  1992cited by this paper
• Tryptase Clara, an activating protease for Sendai virus in rat lungs, is involved in pneumopathogenicity

  1992cited by this paper
• Localisation of a low-molecular-weight bronchial protease inhibitor in the peripheral human lung.

  1983cited by this paper
• Localization of a low molecular weight protease inhibitor in the respiratory tract.

  1980cited by this paper

• Metabolism-dependent endocrine regulation of TMPRSS2 gene expression (rs12329760): proteomic networks and functional pathways of interaction in COVID-19

  2026cites this paper
• Aprotinin (I): Understanding the Role of Host Proteases in COVID-19 and the Importance of Pharmacologically Regulating Their Function

  2024cites this paper
• Salivary antiviral and antibacterial properties in the encounter of SARS-CoV-2.

  2023cites this paper
• The Ubiquitin-Proteasome System Facilitates Membrane Fusion and Uncoating during Coronavirus Entry

  2023cites this paper
• C910 chemical compound inhibits the traffiking of several bacterial AB toxins with cross-protection against influenza virus

  2022cites this paper
• COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development

  2021cites this paper
• Struktur Genom Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

  2021cites this paper
• Coronaviruses, cholesterol and statins: Involvement and application for Covid-19

  2021cites this paper
• Proteases and variants: context matters for SARS-CoV-2 entry assays

  2021cites this paper
• Longitudinal and proteome-wide analyses of antibodies in COVID-19 patients reveal features of the humoral immune response to SARS-CoV-2

  2021cites this paper
• A screening pipeline identifies a broad-spectrum inhibitor of bacterial AB toxins with cross protection against influenza A virus H1N1 and SARS-CoV-2

  2021cites this paper